KALV News and Press, KalVista Pharmaceuticals Inc. From 08/28/23

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting t...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release fea...

– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - – When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents exp...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking pla...

2023-07-07 11:08:15 ET Next week marks the start of a crucial period as earnings season kicks off, with major companies from the financial, consumer, and technology sectors all set to release their quarterly financial results. Among the list of firms scheduled to announce their financia...

2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...

2023-07-07 06:32:55 ET KalVista Pharmaceuticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.77. Cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023, compared to $166.2 million on April 30, 2022. The decrease in the net cash positio...

2023-07-07 06:32:55 ET KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q4 GAAP EPS of -$0.77. Cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023, compared to $166.2 million on April 30, 2022. The decrease in the net cash position...

– Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis – – Real-world patient data show significant burden from HAE still remains on patients receiving modern long-t...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinica...